Global Biotechnology Market Outlook 2025: Driving Growth at 13.0% CAGR | MarketsandMarkets
The global biotechnology industry market size is projected to expand from USD 483.0 billion in 2024 to USD 546.0 billion by 2025, reflecting ...
People14d
The Zepbound Shortage Is Over — Here's What to Expect if You've Been Using an Off-Brand Version
Patients taking a compounded alternative to Eli Lilly's weight loss drug Zepbound will need to transition to the name-brand version in early 2025 Charlotte Phillipp is a Weekend Writer-Reporter at ...
Yahoo Style UK14d
The Zepbound Shortage Is Over — Here's What to Expect if You've Been Using an Off-Brand Version
Eli Lilly’s weight loss drug Zepbound is no longer in short supply, the FDA said, worrying patients who use cheaper, off-brand versions of the drug. On Thursday, Dec. 19, the U.S. Food and Drug ...
The Spokesman-Review15d
FDA approves weight-loss drug Zepbound to treat sleep apnea
The Food and Drug Administration on Friday approved Eli Lilly’s weight-loss drug Zepbound to treat sleep apnea, a common but potentially serious sleep-related breathing disorder, marking it the ...
Tyler Morning Telegraph15d
Medicaid Now Covers GLP-1s for Obesity in Texas
The growing popularity of GLP-1 receptor agonists—including Ozempic and Wegovy from Novo Nordisk, and Mounjaro and Zepbound from Eli Lilly—has added fuel to an already fiery debate over the ...
KHQ15d
Medicaid Now Covers GLP-1s for Obesity in Washington
The growing popularity of GLP-1 receptor agonists—including Ozempic and Wegovy from Novo Nordisk, and Mounjaro and Zepbound from Eli Lilly—has added fuel to an already fiery debate over the ...
People16d
Zepbound Weight Loss Medication Approved by FDA to Treat Sleep Apnea
Shelby Knowles/Bloomberg via Getty The weight loss drug Zepbound, generically known as tirzepatide, is also now an approved medication to treat obstructive sleep apnea, per a Food and Drug ...
McKnight's Long-Term Care News16d
FDA approves Zepbound for sleep apnea in patients with obesity
(HealthDay News) — The US Food and Drug Administration has approved Zepbound (tirzepatide) as the first prescription medication for the treatment of obstructive sleep apnea (OSA). In a news ...
WCVB Channel 5 Boston16d
Some patients want to take a holiday pause on weight-loss drugs. Here's what doctors say
If more than five days have passed, the person should skip the missed dose and administer the next on the regularly scheduled day.It's similar for Mounjaro and Zepbound. The prescribing ...